Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies
暂无分享,去创建一个
A. Fu | Aarti A Patel | Q. Cai | Z. Ding
[1] M. Saruta,et al. Characteristics of adult patients newly diagnosed with Crohn’s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD) , 2022, Journal of Gastroenterology.
[2] Harminder Singh,et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. , 2021, Gastroenterology.
[3] Julia J. Liu. Disparity in the Care of black Inflammatory Bowel Disease Patients. , 2021, Inflammatory bowel diseases.
[4] E. Loftus,et al. Effects of Race and Ethnicity on Diagnosis and Management of Inflammatory Bowel Diseases. , 2020, Gastroenterology.
[5] E. Barnes,et al. Trends and Characteristics of Clinical Trials Participation for Inflammatory Bowel Disease in the United States: A Report From IBD Partners , 2020, Crohn's & colitis 360.
[6] J. Korzenik,et al. South Asian Patients With Inflammatory Bowel Disease in the United States Demonstrate More Fistulizing and Perianal Crohn Phenotype. , 2020, Inflammatory bowel diseases.
[7] Siddharth Singh,et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. , 2020, Gastroenterology.
[8] E. Rupniewska,et al. Real‐world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review , 2019, Journal of clinical pharmacy and therapeutics.
[9] A. Hartzema,et al. Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy. , 2019, Inflammatory bowel diseases.
[10] K. Sugano,et al. Evidence-based clinical practice guidelines for inflammatory bowel disease , 2018, Journal of Gastroenterology.
[11] C. Kin,et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA , 2018, Alimentary pharmacology & therapeutics.
[12] Christopher F. Martin,et al. Asians Have More Perianal Crohn Disease and Ocular Manifestations Compared with White Americans , 2017, Inflammatory Intestinal Diseases.
[13] C. Selinger,et al. Medication adherence in inflammatory bowel disease , 2017, Intestinal research.
[14] J. Im. Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease? , 2017, Intestinal research.
[15] A. López-Sanromán,et al. Management of complex perianal Crohn’s disease , 2016, Annals of gastroenterology.
[16] T. Mikuls,et al. Use of Biologic Therapy in Racial Minorities With Rheumatoid Arthritis From 2 US Health Care Systems , 2017, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[17] Judy H. Cho,et al. Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. , 2017, Gastroenterology.
[18] R. Cross,et al. Racial and Ethnic Minorities with Inflammatory Bowel Disease in the United States: A Systematic Review of Disease Characteristics and Differences , 2016, Inflammatory bowel diseases.
[19] D. Owczarek,et al. Diet and nutritional factors in inflammatory bowel diseases. , 2016, World journal of gastroenterology.
[20] S. Dalal,et al. What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients. , 2015, Gastroenterology & hepatology.
[21] Deena J. Chisolm,et al. Racial Disparities in Readmission, Complications, and Procedures in Children with Crohn's Disease , 2015, Inflammatory bowel diseases.
[22] D. Sachar,et al. Race and Fistulizing Perianal Crohn’s Disease , 2015, Journal of clinical gastroenterology.
[23] R. Odze. A contemporary and critical appraisal of ‘indeterminate colitis’ , 2015, Modern Pathology.
[24] W. Olson,et al. Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy , 2014, Journal of medical economics.
[25] V. Durand. Diagnostic criteria and epidemiology. , 2014 .
[26] R. Panaccione. Mechanisms of inflammatory bowel disease. , 2013, Gastroenterology & hepatology.
[27] L. Peyrin-Biroulet,et al. Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases: A Systematic Review , 2013, Inflammatory Bowel Diseases.
[28] J. Sewell,et al. Systematic Review: The Role of Race and Socioeconomic Factors on IBD Healthcare Delivery and Effectiveness , 2013, Inflammatory bowel diseases.
[29] C. Beauchemin,et al. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database , 2013, BMC Gastroenterology.
[30] C. Carter,et al. Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn’s disease , 2012, Patient preference and adherence.
[31] Subrata Ghosh,et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.
[32] Ning Zhou,et al. Inflammatory bowel disease unclassified , 2011, Journal of Zhejiang University SCIENCE B.
[33] Marie T. Brown,et al. Medication adherence: WHO cares? , 2011, Mayo Clinic proceedings.
[34] G. Hirschfield,et al. Pathogenesis of cholestatic liver disease and therapeutic approaches. , 2010, Gastroenterology.
[35] S. Brant,et al. NOD2 Mutations and Anti-Saccharomyces cerevisiae Antibodies Are Risk Factors for Crohn's Disease in African Americans , 2010, The American Journal of Gastroenterology.
[36] S. Brant,et al. Patient trust‐in‐physician and race are predictors of adherence to medical management in inflammatory bowel disease , 2009, Inflammatory bowel diseases.
[37] A. Repaka,et al. Crohn's Disease in an African-American Population , 2008, The American journal of the medical sciences.
[38] P. Lakatos. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? , 2006, World journal of gastroenterology.
[39] J. Satsangi,et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.
[40] T. Matsui,et al. Crohn’s Disease in Japan: Diagnostic Criteria and Epidemiology , 2000 .
[41] A. Zinsmeister,et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. , 1998, Gastroenterology.
[42] D. Fraser,et al. Epidemiological data of Crohn's disease in Israel: etiological implications. , 1989, Public health reviews.
[43] J. Garisch,et al. Inflammatory bowel disease Cape Town, 1975-1980 , 1983 .